Bud Frazier's 1,000th Implantation of a Ventricular Assist Device

Mark S. Slaughter, MD

*Genius is the very eye of intellect and the wing of
thought; it is always in advance of its time, and is
the pioneer for the generation which it precedes.*

—William Gilmore Simms

Dr. O.H. “Bud” Frazier recently implanted his 1,000th ventricular assist device to help a patient with advanced heart failure. This alone is an amazing feat that is a testament to his surgical skills and the program he has developed for treating patients with advanced heart failure. Although this is monumental and worthy of recognition, it is only a small part of Dr. Frazier’s contributions to the development of mechanical circulatory support (MCS) as a treatment for advanced heart failure.

Dr. Frazier and the heart failure program at the Texas Heart Institute were early participants in and significant contributors to the field of heart transplantation. Through this experience, Dr. Frazier recognized the need to develop a mechanical support solution for patients who were too sick for heart transplantation or were dying on the transplant waiting list. This early recognition of an unmet clinical need resulted in a lifelong commitment to finding an alternative solution for patients dying of heart failure.

Dr. Frazier has been instrumental in the design, development, testing, and subsequent clinical introduction of almost all ventricular assist devices used today. When the initial devices were being developed as an “alternative” to heart transplantation, the main focus was on pulsatile total artificial hearts (TAH). In the course of the development and clinical use of the TAH,¹⁻³ it was recognized that many patients could be adequately supported with restoration of flow and pressure just by the use of a left ventricular assist device (LVAD). Once again, Dr. Frazier and colleagues led the way with their work on pulsatile LVADs.⁴ This work and collaboration with Vic Poirier, PhD, and others resulted in the clinically successful HeartMate IP LVAD.^{5,6} Although many additional advances and iterations of pulsatile devices would follow, Dr. Frazier and others were already looking into the future.

Perhaps one of the greatest contributions to the current state of LVAD technology was the concept of a continuous-flow pump design that would result in diminished pulsatility or perhaps no pulse at all. This radical concept, championed by Dr. Frazier and Dr. Richard Wampler, resulted in the development of the Hemopump.^{7,8} This success with a miniaturized continuous rotary-flow pump redirected the field of MCS and is responsible for the tremendous success of current LVADs.⁹

In addition to his participation in the design and development of many past and current VADs, Dr. Frazier has always been a leader in the clinical introduction and use of these new technologies. This includes the clinical use and indication of LVADs as a bridge to transplantation, for destination therapy, and for myocardial recovery, as well.¹⁰⁻¹⁴

The story does not stop here. His earliest work included transplantation and developing a TAH, and he has continued to pursue this dream. Dr. Frazier seeks to develop a TAH by modifying current continuous-flow pumps into a functional TAH¹⁵⁻¹⁷ and is also teaming with engineers from Australia to develop the BiVACOR® TAH (BiVACOR Pty Ltd.; Brisbane, Australia). Perhaps someday patients will no longer need heart transplantation because of the efforts of Dr. Frazier.

From: Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, Kentucky 40202

Address for reprints:
Mark S. Slaughter, MD,
201 Abraham Flexner Way,
Suite 1200, Louisville, KY
40202

E-mail: mark.slaughter@louisville.edu

© 2014 by the Texas Heart®
Institute, Houston

According to Kurt Dasse, PhD, friend and colleague of Dr. Frazier, “He has an eagerness to always listen to new concepts for mechanical circulatory support. Bud has always been open to mentoring new investigators to assist in advancing their ideas, and willing to pursue practical innovative solutions outside the box. He’s always been the ‘MCS blackboard’ for testing the water on new ideas.”

Dr. Frazier’s impact on patients extends well beyond his 1,000th VAD implantation. Because of his pioneering efforts and willingness to share his knowledge and experience, there are many successful VAD programs around the country and the world and thousands of patients worldwide who have benefited from his work at the Texas Heart Institute.

Dr. Frazier has been a true pioneer. He has helped save the lives of many patients who previously had no option. We are thankful that he has not slowed down and continues to innovate, to contribute, and to mentor future leaders.

References

1. Frazier OH, Akutsu T, Cooley DA. Total artificial heart (TAH) utilization in man. *Trans Am Soc Artif Intern Organs* 1982;28:534-8.
2. Parnis SM, Yu LS, Ochs BD, Macris MP, Frazier OH, Kung RT. Chronic in vivo evaluation of an electrohydraulic total artificial heart. *ASAIO J* 1994;40(3):M489-93.
3. Frazier OH, Dowling RD, Gray LA Jr, Shah NA, Pool T, Gregoric I. The total artificial heart: where we stand. *Cardiology* 2004;101(1-3):117-21.
4. Norman JC, Duncan JM, Frazier OH, Hallman GL, Ott DA, Reul GJ, Cooley DA. Intracorporeal (abdominal) left ventricular assist devices or partial artificial hearts: a five-year clinical experience. *Arch Surg* 1981;116(11):1441-5.
5. Frazier OH, Rose EA, Macmanus Q, Burton NA, Lefrak EA, Poirier VL, Dasse KA. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. *Ann Thorac Surg* 1992;53(6):1080-90.
6. Frazier OH, Rose EA, McCarthy P, Burton NA, Tector A, Levin H, et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. *Ann Surg* 1995;222(3):327-38.
7. Wampler RK, Moise JC, Frazier OH, Olsen DB. In vivo evaluation of a peripheral vascular access axial flow blood pump. *ASAIO Trans* 1988;34(3):450-4.
8. Frazier OH, Wampler RK, Duncan JM, Dear WE, Macris MP, Parnis SM, Fuqua JM. First human use of the Hemopump, a catheter-mounted ventricular assist device. *Ann Thorac Surg* 1990;49(2):299-304.
9. Frazier OH, Jacob LP. Small pumps for ventricular assistance: progress in mechanical circulatory support. *Cardiol Clin* 2007;25(4):553-64; vi.
10. Frazier OH, Rose EA, Oz MC, Dembitsky W, McCarthy P, Radovancevic B, et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. *J Thorac Cardiovasc Surg* 2001;122(6):1186-95.
11. Frazier OH, Gemmato C, Myers TJ, Gregoric ID, Radovancevic B, Loyalka P, Kar B. Initial clinical experience with the HeartMate II axial-flow left ventricular assist device. *Tex Heart Inst J* 2007;34(3):275-81.
12. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med* 2001;345(20):1435-43.
13. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. *N Engl J Med* 2009;361(23):2241-51.
14. Frazier OH, Myers TJ. Left ventricular assist system as a bridge to myocardial recovery. *Ann Thorac Surg* 1999;68(2):734-41.
15. Cohn WE, Handy KM, Parnis SM, Conger JL, Winkler JA, Frazier OH. Eight-year experience with a continuous-flow total artificial heart in calves. *ASAIO J* 2014;60(1):25-30.
16. Cohn WE, Winkler JA, Parnis S, Costas GG, Beathard S, Conger J, Frazier OH. Ninety-day survival of a calf implanted with a continuous-flow total artificial heart. *ASAIO J* 2014;60(1):15-8.
17. Frazier OH, Cohn WE. Continuous-flow total heart replacement device implanted in a 55-year-old man with end-stage heart failure and severe amyloidosis. *Tex Heart Inst J* 2012;39(4):542-6.